- UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company
- Recombinant human albumin is a critical component in the manufacture of innovative biopharmaceuticals, particularly for modalities such as cell therapies, viral therapies and vaccines
- Sartorius will acquire all outstanding shares of Albumedix Ltd. for approximately £415 million
Göttingen - The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies. The business, founded in 1984, has more than 100 employees and is expected to generate revenue of approximately £33 million in 2022 with a significant double-digit EBITDA margin. The agreed purchase price amounts to approximately £415 million. The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022.
“Albumedix will be an important addition to Sartorius’ advanced therapy solutions, particularly regarding our cell culture media business, as it will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical ancillary materials. This market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications. Albumedix will also add important formulation excipients to our vaccine production solutions, allowing us to expand our existing customer relationships and forge new ones,” said René Fáber, member of the Executive Board for the Bioprocess Solutions Division of Sartorius.
“We are delighted to be joining forces with Sartorius and look forward to accelerating our ambitious growth plans in delivering critical solutions to our global customers. We have been highly impressed with Sartorius’ knowledge and capabilities in the bioprocessing markets, and we are excited to join this purposeful journey. We believe Sartorius will bring tremendous value in strengthening our market reach and broadening our innovation capacity, as well as significantly scaling up our existing platform. We remain focused on our promise of empowering excellence in the life science industry,” said Jonas S. Møller, CEO of Albumedix.
Albumedix will be part of the Bioprocess Solutions Division, and the existing 72,000-square-foot site in Nottingham will be established as a center of excellence for innovation and GMP-compliant production of critical raw materials.
Milbank LLP provided legal counsel to Sartorius in this transaction. William Blair acted as financial advisor to Albumedix, and Eversheds Sutherland provided legal counsel.
Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany
Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines New penicillin production process will significantly improve ecological footprint and help...
Air Products to Build Europe’s Largest Blue Hydrogen Plant and Strengthens Long-term Agreement in Rotterdam, The Netherlands
The facility is expected to be on-stream in 2026, and the resulting "blue" hydrogen product to serve ExxonMobil’s (Esso) Rotterdam refinery and additional customers via Air Products' hydrogen pipel...
OMV and Interzero establish joint venture to build and operate Europe’s largest sorting facility for chemical recycling in Walldürn, Germany
innovative, fully automatic, sorting plant with capacity of up to 260,000 tonnes per year. Mixed plastics into feedstock for OMV’s chemical recycling. Investment volume over EUR 170 mn
Carbios obtains building and operating permits, in line with announced schedule, for world’s first PET biorecycling plant in Longlaville, France
This authorization allows construction work to start as planned for the plant’s commissioning in 2025. The plant will have a capacity of 50,000 tons of PET waste and will create 150 jobs